2009 年 69 巻 5 号 p. 392-398
Primary care of periodontitis is to remove the bacterial biofilm around teeth. Periodontal surgery is performed unless the disease was not cured by primary treatment. Flap operation is conventional periodontal surgery performed most often in Japan (400,000 cases/year). This surgery, covered by insurance, removes the infected tissues by separating gingival tissues from root surfaces. However, if periodontal tissue cannot regenerate, novel treatment is required.
The recombinant human basic fibroblast growth factor (rhbFGF), was reported to stimulate proliferation of human periodontal ligament-derived cells subcultured from periodontal tissues.
In this study, the demands on the formulation rhbFGF applied to periodontitis are listed does not leak and diffuses easily at the application site, can be administered to maxillary side, and has appropriate extrusion resistance when administered with syringe even if the amount is less than 1mL. To achieve the demands above, a viscosity is needed as a concept of drug formulation.
In addition, a viscous formulation is expected to improve the rhbFGF remaining at the application site. In order to clarify the selection criteria for viscous additives, viscosity, extrusion, flow characteristics and in vitro drug releasing test were examined using hydroxypropylcellulose as a model additive. Desired formulation characteristics and increased remaining amount of drug at the application site were confirmed.
Furthermore, the issue of viscous formulation as a final administration form reveals that it is necessary to improve the reconstituted characteristic when rhbFGF lyophilized cake is reconstituted using viscous solution.
